Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Revolution Medicines, Inc. (RVMD)
USD183.95
-2.93 (-1.57%)
US NASDAQ Healthcare Biotechnology
Address
700 Saginaw Drive 94063
Redwood City, CA, US
Redwood City, CA, US
CEO
Mark A. Goldsmith
Website
revmed.com
IPO
2020-02-13
CIK 1628171 ISIN US76155X1000
Also trades on
NASDAQ Global Select · RVMD (USD)
NASDAQ Global Select · RVMDW (USD)
Description
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
News Sentiment (7d)
4 articles
- Better Growth Buy: Axsome vs Revolution Medicines The Motley Fool
- European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process GlobeNewsWire
- 5 Stock Setups Where Wall Street Sees the Most Upside Right Now 247 Wallst
- EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill Reuters
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| EQRx, Inc. | EQRX | 2023-09-13 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD183.95
-2.93 (-1.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.41
Float Shares
179.91M
Free Float %
84.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.09% | -2.07% | +51.11% | +49.72% | +121.36% | +82.95% | +247.95% | +463.28% | +360.41% | +404.22% | +404.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
183.95
Low
73.00
-60.3%
Consensus
157.80
-14.2%
Median
163.50
-11.1%
High
205.00
+11.4%
DCF (Unlevered)
0.88
-99.5%
DCF (Levered)
1.18
-99.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 17 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 5 |
174.20
-5.3%
|
| Last Quarter | 6 |
169.17
-8.0%
|
| Last Year | 20 |
128.10
-30.4%
|
| All Time | 36 |
95.72
-48.0%
|
Quality scores
Altman Z-Score
20.84
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-66.2% Q1'26: -102.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +708.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.4% Q1'26: +5.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.15× Q1'26: -0.09× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 15 Rev. Ana. 17 EPS Ana. |
Dec 2027 13 Rev. Ana. 15 EPS Ana. |
Dec 2028 14 Rev. Ana. 14 EPS Ana. |
Dec 2029 9 Rev. Ana. 8 EPS Ana. |
Dec 2030 13 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
42.98M
est: 50.97M (-15.7%)
|
29.39M
est: 28.78M (+2.1%)
|
35.38M
est: 27.86M (+27.0%)
|
11.58M
est: 742.0K (+1,460.6%)
|
—
est: 300.0K (-100.0%)
|
—
est: 3.48M (-100.0%)
|
97.42M
8.69M – 187.98M
+2,696.1% YoY
|
781.04M
148.67M – 2.09B
+701.7% YoY
|
1.76B
1.72B – 1.80B
+125.1% YoY
|
3.44B
595.50M – 9.27B
+95.7% YoY
|
5.30B
917.01M – 14.28B
+54.0% YoY
|
| EBITDA |
-101.91M
est: -30.58M (-233.3%)
|
-179.75M
est: -161.41M (-11.4%)
|
-248.62M
est: -179.09M (-38.8%)
|
-477.88M
est: -148.4K (-321,921.0%)
|
-677.70M
est: -60.0K (-1,129,418.8%)
|
-1.09B
est: -696.8K (-156,393.4%)
|
-19.48M
-37.60M – -1.74M
-2,696.1% YoY
|
-156.21M
-417.14M – -29.73M
-701.7% YoY
|
-351.67M
-359.59M – -343.74M
-125.1% YoY
|
-688.34M
-1.85B – -119.10M
-95.7% YoY
|
-1.06B
-2.86B – -183.40M
-54.0% YoY
|
| EBIT |
-108.46M
est: -30.58M (-254.7%)
|
-187.08M
est: -168.88M (-10.8%)
|
-258.28M
est: -187.48M (-37.8%)
|
-487.19M
est: -148.4K (-328,194.0%)
|
-689.52M
est: -60.0K (-1,149,125.8%)
|
-1.11B
est: -696.8K (-158,769.6%)
|
-19.48M
-37.60M – -1.74M
-2,696.1% YoY
|
-156.21M
-417.14M – -29.73M
-701.7% YoY
|
-351.67M
-359.59M – -343.74M
-125.1% YoY
|
-688.34M
-1.85B – -119.10M
-95.7% YoY
|
-1.06B
-2.86B – -183.40M
-54.0% YoY
|
| Net Income |
-108.16M
est: -306.29M (+64.7%)
|
-187.09M
est: -168.05M (-11.3%)
|
-248.71M
est: -296.23M (+16.0%)
|
-436.37M
est: -519.21M (+16.0%)
|
-600.09M
est: -696.21M (+13.8%)
|
-1.13B
est: -1.05B (-8.1%)
|
-1.46B
-1.60B – -1.33B
-40.0% YoY
|
-1.07B
-2.26B – 202.37M
+26.8% YoY
|
-290.81M
-2.36B – 1.71B
+72.9% YoY
|
651.36M
-48.90M – 2.09B
+324.0% YoY
|
1.80B
-134.99M – 5.76B
+176.1% YoY
|
| SGA |
21.43M
est: 92.12M (-76.7%)
|
30.45M
est: 27.45M (+10.9%)
|
40.59M
est: 50.36M (-19.4%)
|
75.62M
est: 1.59M (+4,656.4%)
|
97.30M
est: 642.8K (+15,036.5%)
|
187.13M
est: 7.47M (+2,406.5%)
|
208.75M
18.62M – 402.78M
+2,696.1% YoY
|
1.67B
318.56M – 4.47B
+701.7% YoY
|
3.77B
3.68B – 3.85B
+125.1% YoY
|
7.37B
1.28B – 19.87B
+95.7% YoY
|
11.36B
1.96B – 30.59B
+54.0% YoY
|
| EPS |
-1.62
est: -1.83 (+11.3%)
|
-2.47
est: -2.50 (+1.3%)
|
-3.08
est: -3.29 (+6.4%)
|
-3.86
est: -3.58 (-7.9%)
|
-3.58
est: -3.47 (-3.1%)
|
-5.95
est: -5.65 (-5.4%)
|
-7.91
-8.40 – -7.00
-40.1% YoY
|
-5.54
-11.91 – 1.06
+29.9% YoY
|
-1.99
-12.42 – 8.99
+64.2% YoY
|
3.43
-0.26 – 10.97
+272.5% YoY
|
9.46
-0.71 – 30.29
+176.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-22 | Leerink Partners | Outperform | Outperform | Maintain |
| 2026-04-20 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.06B
OE per share TTM
-5.51
Owner's Yield
-3.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
352.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
104
Total invested
331.94M
Insider transactions (90d)
1
Beneficial owners (>5%)
47
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF Inc. | 7.56M | 7.10% | — | — | — | 7.56M | CO | Delaware | 2023-06-30 | ↗ |
| 2 | BVF Partners L.P. | 7.56M | 7.10% | — | — | — | 7.56M | IA, PN | Delaware | 2023-06-30 | ↗ |
| 3 | Mark N. Lampert | 7.56M | 7.10% | — | — | — | 7.56M | IN | Delaware | 2023-06-30 | ↗ |
| 4 | BVF GP Holdings LLC | 7.17M | 6.70% | — | — | — | 7.17M | OO | Delaware | 2023-06-30 | ↗ |
| 5 | Andrew J. M. Spokes | 6.76M | 6.20% | — | 6.76M | — | — | IN | United Kingdom | 2023-11-09 | ↗ |
| 6 | Daniel S. Short | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 7 | David T. Kim | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 8 | Edric C. Saito | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 9 | Hannah E. Dunn | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 10 | John R. Warren | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 11 | Joshua J. Dapice | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 12 | Mark C. Wehrly | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 13 | Michael G. Linn | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 14 | Nicolas Giauque | 6.76M | 6.20% | — | 6.76M | — | — | IN | France | 2023-11-09 | ↗ |
| 15 | Philip D. Dreyfuss | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 16 | Rajiv A. Patel | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 17 | Richard B. Fried | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 18 | Thomas G. Roberts, Jr. | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 19 | Varun N. Gehani | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 20 | William Seybold | 6.76M | 6.20% | — | 6.76M | — | — | IN | United States | 2023-11-09 | ↗ |
| 21 | Farallon Partners, L.L.C. | 6.50M | 5.90% | — | 6.50M | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 22 | Mark Levin | 5.65M | 7.70% | 129.3K | 5.52M | 129.3K | 5.52M | IN | — | 2022-02-14 | ↗ |
| 23 | BVF I GP LLC | 4.64M | 4.40% | — | — | — | 4.64M | OO | Delaware | 2023-06-30 | ↗ |
| 24 | Biotechnology Value Fund, L.P. | 4.64M | 4.40% | — | — | — | 4.64M | PN | Delaware | 2023-06-30 | ↗ |
| 25 | BB Biotech AG | 4.60M | 5.20% | — | 4.60M | — | 4.60M | HC, CO | Switzerland | 2022-09-30 | ↗ |
| 26 | Biotech Growth N.V. | 4.60M | 5.20% | — | 4.60M | — | 4.60M | CO | Switzerland | 2022-09-30 | ↗ |
| 27 | EcoR1 Capital, LLC | 4.48M | 11.00% | — | 4.48M | — | 4.48M | IA, OO | Delaware | 2023-01-23 | ↗ |
| 28 | Oleg Nodelman | 4.48M | 11.00% | — | 4.48M | — | 4.48M | HC, IN | Delaware | 2023-01-23 | ↗ |
| 29 | EcoR1 Capital Fund Qualified, L.P. | 4.22M | 11.00% | — | 4.22M | — | 4.22M | PN | Delaware | 2023-01-23 | ↗ |
| 30 | Farallon Healthcare Partners (GP), L.L.C. | 3.77M | 3.40% | — | 3.77M | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 31 | Farallon Healthcare Partners Master, L.P. | 3.77M | 3.40% | — | 3.77M | — | — | PN | Cayman Islands | 2023-11-09 | ↗ |
| 32 | BVF II GP LLC | 2.53M | 2.40% | — | — | — | 2.53M | OO | Delaware | 2023-06-30 | ↗ |
| 33 | Biotechnology Value Fund II, L.P. | 2.53M | 2.40% | — | — | — | 2.53M | PN | Delaware | 2023-06-30 | ↗ |
| 34 | TRV GP IV, LLC | 1.42M | 1.90% | — | 1.42M | — | 1.42M | OO | — | 2022-02-14 | ↗ |
| 35 | Third Rock Ventures IV, L.P. | 1.42M | 1.90% | — | 1.42M | — | 1.42M | PN | — | 2022-02-14 | ↗ |
| 36 | Farallon Capital Offshore Investors II, L.P. | 1.20M | 1.10% | — | 1.20M | — | — | PN | Cayman Islands | 2023-11-09 | ↗ |
| 37 | Farallon Capital Institutional Partners, L.P. | 761.7K | 0.70% | — | 761.7K | — | — | PN | California | 2023-11-09 | ↗ |
| 38 | BVF Partners OS Ltd. | 294.8K | 1.00% | — | — | — | 294.8K | CO | Delaware | 2023-06-30 | ↗ |
| 39 | Biotechnology Value Trading Fund OS LP | 294.8K | 1.00% | — | — | — | 294.8K | PN | Delaware | 2023-06-30 | ↗ |
| 40 | Farallon Capital Partners, L.P. | 291.6K | 0.30% | — | 291.6K | — | — | PN | California | 2023-11-09 | ↗ |
| 41 | Farallon Capital F5 Master I, L.P. | 261.9K | 0.20% | — | 261.9K | — | — | PN | Cayman Islands | 2023-11-09 | ↗ |
| 42 | Farallon F5 (GP), L.L.C. | 261.9K | 0.20% | — | 261.9K | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 43 | Farallon Capital Institutional Partners II, L.P. | 205.4K | 0.20% | — | 205.4K | — | — | PN | California | 2023-11-09 | ↗ |
| 44 | Farallon Institutional (GP) V, L.L.C. | 118.8K | 0.10% | — | 118.8K | — | — | OO | Delaware | 2023-11-09 | ↗ |
| 45 | Four Crossings Institutional Partners V, L.P. | 118.8K | 0.10% | — | 118.8K | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 46 | Farallon Capital Institutional Partners III, L.P. | 90.0K | 0.10% | — | 90.0K | — | — | PN | Delaware | 2023-11-09 | ↗ |
| 47 | Farallon Capital (AM) Investors, L.P. | 63.9K | 0.10% | — | 63.9K | — | — | PN | Delaware | 2023-11-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
104
-301 vs prev Q
New positions
38
Closed positions
324
Increased
68
Reduced
19
Put/Call ratio
0.00
Calls held
100.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 900.4K +900.4K (+100.0%) | 71.72B +71.7B (+100.0%) | 0.48% +0.476 pp | 67.21% +67.206 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 2 | MASS GENERAL BRIGHAM, INC | 344.1K +344.1K (+100.0%) | 27.41B +27.4B (+100.0%) | 0.18% +0.182 pp | 3.38% +3.385 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 16.72M +1.1M (+6.7%) | 1.33B +600.3M (+82.1%) | 8.84% +0.511 pp | 0.02% +0.008 pp | USD33.97 +134.5% | 24 qtrs — |
| 4 | FARALLON CAPITAL MANAGEMENT LLC | 14.58M -42.9K (-0.3%) | 1.16B +478.5M (+70.1%) | 7.71% -0.067 pp | 5.48% +2.685 pp | USD35.28 +125.8% | 20 qtrs — |
| 5 | JANUS HENDERSON GROUP PLC | 12.30M +947.4K (+8.3%) | 980.04M +449.7M (+84.8%) | 6.50% +0.466 pp | 0.44% +0.197 pp | USD41.10 +93.8% | 13 qtrs — |
| 6 | BAKER BROS. ADVISORS LP | 9.46M +— (+0.0%) | 753.12M +311.6M (+70.6%) | 5.00% -0.029 pp | 4.41% +1.219 pp | USD30.02 +165.3% | 20 qtrs — |
| 7 | BLACKROCK, INC. | 8.93M +598.9K (+7.2%) | 711.01M +322.1M (+82.8%) | 4.72% +0.291 pp | 0.01% +0.005 pp | USD47.56 +67.5% | 6 qtrs — |
| 8 | FMR LLC | 8.59M -813.7K (-8.7%) | 684.03M +245.0M (+55.8%) | 4.54% -0.459 pp | 0.03% +0.012 pp | USD34.92 +128.1% | 24 qtrs — |
| 9 | NEXTECH INVEST, LTD. | 7.60M +— (+0.0%) | 605.43M +250.5M (+70.6%) | 4.02% -0.023 pp | 58.53% +4.497 pp | USD35.36 +125.3% | 4 qtrs — |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 6.99M -2.8M (-28.8%) | 556.57M +98.3M (+21.4%) | 3.69% -1.523 pp | 0.10% +0.017 pp | USD29.28 +172.0% | 24 qtrs — |
| 11 | PARADIGM BIOCAPITAL ADVISORS LP | 6.64M +421.1K (+6.8%) | 529.23M +238.6M (+82.1%) | 3.51% +0.204 pp | 13.51% +5.243 pp | USD39.55 +101.4% | 8 qtrs — |
| 12 | BELLEVUE GROUP AG | 5.01M -568.1K (-10.2%) | 398.71M +138.4M (+53.2%) | 2.65% -0.317 pp | 7.56% +2.147 pp | USD32.88 +142.2% | 21 qtrs — |
| 13 | STATE STREET CORP | 4.11M -1.1M (-21.8%) | 327.30M +81.9M (+33.4%) | 2.17% -0.621 pp | 0.01% +0.003 pp | USD31.41 +153.6% | 24 qtrs — |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.40M -469.0K (-12.1%) | 271.19M +90.3M (+49.9%) | 1.80% -0.260 pp | 0.03% +0.010 pp | USD26.93 +195.8% | 24 qtrs — |
| 15 | BVF INC/IL | 3.36M -618.1K (-15.6%) | 267.37M +81.7M (+44.0%) | 1.77% -0.339 pp | 9.00% +1.475 pp | USD30.42 +161.8% | 24 qtrs — |
| 16 | ALPHABET INC. | 3.35M -788.2K (-19.1%) | 266.44M +73.4M (+38.0%) | 1.77% -0.429 pp | 10.33% +2.314 pp | USD28.69 +177.6% | 9 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 3.16M +16.3K (+0.5%) | 251.91M +105.0M (+71.4%) | 1.67% -0.001 pp | 0.02% +0.006 pp | USD33.15 +140.3% | 24 qtrs — |
| 18 | UBS GROUP AG | 3.09M +2.0M (+183.6%) | 245.95M +195.1M (+383.6%) | 1.63% +1.053 pp | 0.04% +0.032 pp | USD65.95 +20.8% | 24 qtrs — |
| 19 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.89M -755.7K (-20.7%) | 230.56M +60.1M (+35.2%) | 1.53% -0.411 pp | 2.94% +0.342 pp | USD29.54 +169.6% | 24 qtrs — |
| 20 | WESTFIELD CAPITAL MANAGEMENT CO LP | 2.85M +331.0K (+13.2%) | 226.61M +109.2M (+93.0%) | 1.50% +0.167 pp | 0.94% +0.451 pp | USD44.27 +79.9% | 5 qtrs — |
| 21 | GENERAL ATLANTIC, L.P. | 2.81M +338.5K (+13.7%) | 224.05M +108.5M (+93.9%) | 1.49% +0.171 pp | 7.80% +4.330 pp | USD50.67 +57.2% | 2 qtrs — |
| 22 | CASDIN CAPITAL, LLC | 2.58M -70.0K (-2.6%) | 205.28M +81.7M (+66.0%) | 1.36% -0.045 pp | 12.75% +2.443 pp | USD28.23 +182.1% | 24 qtrs — |
| 23 | WOODLINE PARTNERS LP | 2.50M -415.0K (-14.2%) | 199.20M +63.0M (+46.3%) | 1.32% -0.228 pp | 0.77% +0.131 pp | USD27.48 +189.8% | 24 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 2.49M +1.8M (+237.6%) | 198.45M +164.0M (+475.8%) | 1.32% +0.924 pp | 0.02% +0.020 pp | USD67.27 +18.4% | 24 qtrs — |
| 25 | NORGES BANK | 2.46M +2.5M (+100.0%) | 195.57M +195.6M (+100.0%) | 1.30% +1.298 pp | 0.02% +0.021 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 26 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.21M +1.5M (+197.1%) | 175.67M +141.0M (+406.7%) | 1.17% +0.771 pp | 0.27% +0.211 pp | USD67.50 +18.0% | 10 qtrs — |
| 27 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 2.20M -2.6M (-54.0%) | 175.26M -48.1M (-21.5%) | 1.16% -1.379 pp | 0.11% -0.026 pp | USD36.48 +118.3% | 4 qtrs — |
| 28 | LUNATE CAPITAL LTD | 2.20M +— (+0.0%) | 174.93M +72.4M (+70.6%) | 1.16% -0.007 pp | 66.20% +50.738 pp | USD35.36 +125.3% | 4 qtrs — |
| 29 | AVORO CAPITAL ADVISORS LLC | 2.17M +2.2M (+100.0%) | 172.84M +172.8M (+100.0%) | 1.15% +1.147 pp | 1.66% +1.662 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 30 | AMERIPRISE FINANCIAL INC | 2.06M +832.1K (+67.9%) | 163.83M +106.6M (+186.4%) | 1.09% +0.436 pp | 0.04% +0.024 pp | USD50.54 +57.6% | 24 qtrs — |
| 31 | POLAR CAPITAL HOLDINGS PLC | 2.01M +1.5M (+321.2%) | 160.40M +138.1M (+618.4%) | 1.06% +0.810 pp | 0.62% +0.512 pp | USD71.12 +12.0% | 5 qtrs — |
| 32 | LOGOS GLOBAL MANAGEMENT LP | 2.00M +250.0K (+14.3%) | 159.30M +77.6M (+94.9%) | 1.06% +0.127 pp | 9.63% +2.301 pp | USD44.37 +79.5% | 10 qtrs — |
| 33 | HOLOCENE ADVISORS, LP | 1.91M -1.5M (-44.5%) | 151.97M -8.6M (-5.3%) | 1.01% -0.819 pp | 0.32% -0.047 pp | USD30.38 +162.2% | 12 qtrs — |
| 34 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.68M +48.3K (+3.0%) | 134.11M +57.7M (+75.6%) | 0.89% +0.021 pp | 0.02% +0.009 pp | USD37.45 +112.7% | 24 qtrs — |
| 35 | D. E. SHAW & CO., INC. | 1.61M +801.5K (+98.7%) | 128.53M +90.6M (+238.8%) | 0.85% +0.421 pp | 0.07% +0.049 pp | USD59.01 +35.0% | 14 qtrs — |
| 36 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 1.34M +— (+0.0%) | 106.35M +44.0M (+70.6%) | 0.71% -0.004 pp | 5.45% +1.810 pp | USD29.39 +171.0% | 12 qtrs — |
| 37 | SIREN, L.L.C. | 1.34M +291.4K (+27.9%) | 106.34M +57.6M (+118.2%) | 0.71% +0.151 pp | 3.17% +1.265 pp | USD50.54 +57.6% | 6 qtrs — |
| 38 | CITADEL ADVISORS LLC | 1.30M +122.3K (+10.4%) | 103.73M +48.6M (+88.2%) | 0.69% +0.061 pp | 0.02% +0.007 pp | USD40.13 +98.5% | 24 qtrs — |
| 39 | CALIGAN PARTNERS LP | 1.28M +219.7K (+20.6%) | 102.26M +52.6M (+105.8%) | 0.68% +0.113 pp | 8.42% +1.909 pp | USD46.90 +69.8% | 4 qtrs — |
| 40 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.20M +800.0K (+200.0%) | 95.58M +76.9M (+411.7%) | 0.63% +0.422 pp | 4.75% +3.482 pp | USD65.49 +21.6% | 12 qtrs — |
| 41 | DIMENSIONAL FUND ADVISORS LP | 1.16M -279.2K (-19.4%) | 92.53M +25.2M (+37.5%) | 0.61% -0.152 pp | 0.02% +0.005 pp | USD36.36 +119.1% | 18 qtrs — |
| 42 | JEFFERIES FINANCIAL GROUP INC. | 1.14M +1.1M (+8,678.4%) | 90.90M +90.3M (+14,872.2%) | 0.60% +0.596 pp | 0.46% +0.462 pp | USD79.16 +0.6% | 5 qtrs — |
| 43 | PICTET ASSET MANAGEMENT HOLDING SA | 1.14M -174.6K (-13.3%) | 90.65M +29.5M (+48.2%) | 0.60% -0.096 pp | 0.09% +0.029 pp | USD42.67 +86.7% | 8 qtrs — |
| 44 | JANE STREET GROUP, LLC | 1.09M +493.0K (+82.5%) | 86.85M +59.0M (+211.3%) | 0.58% +0.259 pp | 0.01% +0.009 pp | USD55.94 +42.4% | 16 qtrs — |
| 45 | FRANKLIN RESOURCES INC | 1.06M +108.7K (+11.4%) | 84.44M +40.0M (+90.0%) | 0.56% +0.055 pp | 0.02% +0.010 pp | USD47.72 +66.9% | 3 qtrs — |
| 46 | CANDRIAM S.C.A. | 1.03M +162.3K (+18.7%) | 82.12M +41.6M (+102.4%) | 0.54% +0.083 pp | 0.41% +0.197 pp | USD40.15 +98.4% | 19 qtrs — |
| 47 | HOOD RIVER CAPITAL MANAGEMENT LLC | 945.6K +17.5K (+1.9%) | 75.32M +32.0M (+73.8%) | 0.50% +0.006 pp | 0.83% +0.314 pp | USD42.03 +89.5% | 7 qtrs — |
| 48 | AH CAPITAL MANAGEMENT, L.L.C. | 921.1K -1.8M (-66.5%) | 73.37M -55.0M (-42.8%) | 0.49% -0.974 pp | 4.64% -4.558 pp | USD28.68 +177.7% | 9 qtrs — |
| 49 | BANK OF AMERICA CORP /DE/ | 879.8K +126.0K (+16.7%) | 70.08M +34.9M (+99.1%) | 0.47% +0.064 pp | 0.01% +0.003 pp | USD41.52 +91.8% | 24 qtrs — |
| 50 | NORTHERN TRUST CORP | 850.3K -9.2K (-1.1%) | 67.73M +27.6M (+68.7%) | 0.45% -0.008 pp | 0.01% +0.004 pp | USD32.27 +146.8% | 24 qtrs — |
| 51 | MILLENNIUM MANAGEMENT LLC | 800.1K +371.8K (+86.8%) | 63.73M +43.7M (+218.6%) | 0.42% +0.195 pp | 0.03% +0.018 pp | USD56.62 +40.7% | 4 qtrs — |
| 52 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 797.5K -200.0K (-20.1%) | 63.52M +16.9M (+36.4%) | 0.42% -0.109 pp | 1.71% +0.310 pp | USD22.52 +253.7% | 12 qtrs — |
| 53 | CAPTION MANAGEMENT, LLC | 736.1K +220.1K (+42.7%) | 58.63M +34.5M (+143.3%) | 0.39% +0.115 pp | 0.40% +0.214 pp | USD52.58 +51.5% | 5 qtrs — |
| 54 | MORGAN STANLEY | 651.7K -782.9K (-54.6%) | 51.91M -15.1M (-22.5%) | 0.34% -0.418 pp | 0.00% -0.001 pp | USD36.66 +117.3% | 24 qtrs — |
| 55 | FIRST TURN MANAGEMENT, LLC | 638.4K -4.7K (-0.7%) | 50.85M +20.8M (+69.3%) | 0.34% -0.004 pp | 5.81% +1.301 pp | USD43.97 +81.1% | 7 qtrs — |
| 56 | BNP PARIBAS ARBITRAGE, SNC | 619.4K +194.7K (+45.8%) | 49.33M +29.5M (+148.8%) | 0.33% +0.102 pp | 0.02% +0.012 pp | USD52.69 +51.2% | 5 qtrs — |
| 57 | DAFNA CAPITAL MANAGEMENT LLC | 604.5K -52.7K (-8.0%) | 48.15M +17.5M (+56.9%) | 0.32% -0.030 pp | 11.18% +3.602 pp | USD31.41 +153.6% | 21 qtrs — |
| 58 | BANK OF NEW YORK MELLON CORP | 542.1K +12.8K (+2.4%) | 43.18M +18.5M (+74.7%) | 0.29% +0.005 pp | 0.01% +0.003 pp | USD32.91 +142.0% | 24 qtrs — |
| 59 | MIC CAPITAL MANAGEMENT UK LLP | 508.6K +— (+0.0%) | 40.51M +16.8M (+70.6%) | 0.27% -0.002 pp | 9.18% +4.433 pp | USD28.68 +177.7% | 9 qtrs — |
| 60 | BIOIMPACT CAPITAL LLC | 505.7K +190.0K (+60.2%) | 40.28M +25.5M (+173.2%) | 0.27% +0.099 pp | 4.61% +2.195 pp | USD47.10 +69.1% | 18 qtrs — |
| 61 | ROYAL BANK OF CANADA | 503.7K +311.4K (+161.9%) | 40.12M +31.1M (+346.7%) | 0.27% +0.164 pp | 0.01% +0.005 pp | USD65.39 +21.8% | 24 qtrs — |
| 62 | AMERICAN CENTURY COMPANIES INC | 467.4K +16.3K (+3.6%) | 37.23M +16.2M (+76.7%) | 0.25% +0.007 pp | 0.02% +0.008 pp | USD40.69 +95.7% | 13 qtrs — |
| 63 | POINT72 ASSET MANAGEMENT, L.P. | 446.6K +446.6K (+100.0%) | 35.57M +35.6M (+100.0%) | 0.24% +0.236 pp | 0.04% +0.040 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 64 | TCG CROSSOVER MANAGEMENT, LLC | 436.5K +— (+0.0%) | 34.77M +14.4M (+70.6%) | 0.23% -0.001 pp | 1.15% +0.148 pp | USD46.70 +70.6% | 2 qtrs — |
| 65 | FRONTIER CAPITAL MANAGEMENT CO LLC | 430.8K +308.0K (+250.8%) | 34.31M +28.6M (+498.4%) | 0.23% +0.162 pp | 0.36% +0.313 pp | USD67.14 +18.6% | 4 qtrs — |
| 66 | TWO SIGMA INVESTMENTS, LP | 421.7K +412.6K (+4,530.9%) | 33.59M +33.2M (+7,798.3%) | 0.22% +0.218 pp | 0.05% +0.047 pp | USD78.94 +0.9% | 2 qtrs — |
| 67 | JPMORGAN CHASE & CO | 421.6K -2.1M (-83.1%) | 33.58M -83.1M (-71.2%) | 0.22% -1.105 pp | 0.00% -0.005 pp | USD30.48 +161.3% | 24 qtrs — |
| 68 | NUVEEN, LLC | 406.2K +68.8K (+20.4%) | 32.36M +16.6M (+105.3%) | 0.21% +0.035 pp | 0.01% +0.004 pp | USD45.09 +76.6% | 4 qtrs — |
| 69 | BOXER CAPITAL MANAGEMENT, LLC | 400.0K +— (+0.0%) | 31.86M +13.2M (+70.6%) | 0.21% -0.001 pp | 6.97% +1.019 pp | USD43.74 +82.1% | 5 qtrs — |
| 70 | LORD, ABBETT & CO. LLC | 399.5K +399.5K (+100.0%) | 31.82M +31.8M (+100.0%) | 0.21% +0.211 pp | 0.10% +0.098 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 71 | MARSHALL WACE, LLP | 386.2K +225.1K (+139.7%) | 30.76M +23.2M (+308.9%) | 0.20% +0.119 pp | 0.03% +0.020 pp | USD65.15 +22.3% | 10 qtrs — |
| 72 | EVENTIDE ASSET MANAGEMENT, LLC | 378.3K -216.8K (-36.4%) | 30.13M +2.3M (+8.4%) | 0.20% -0.116 pp | 0.47% +0.014 pp | USD37.58 +111.9% | 11 qtrs — |
| 73 | TD ASSET MANAGEMENT INC | 370.5K -165.1K (-30.8%) | 29.51M +4.5M (+18.0%) | 0.20% -0.089 pp | 0.02% +0.003 pp | USD33.07 +140.9% | 19 qtrs — |
| 74 | CHECKPOINT CAPITAL L.P. | 370.0K -122.3K (-24.8%) | 29.47M +6.5M (+28.2%) | 0.20% -0.066 pp | 9.21% +1.504 pp | USD42.80 +86.1% | 5 qtrs — |
| 75 | INVESCO LTD. | 367.9K +166.9K (+83.1%) | 29.30M +19.9M (+212.2%) | 0.19% +0.088 pp | 0.00% +0.003 pp | USD55.05 +44.7% | 23 qtrs — |
| 76 | UBS ASSET MANAGEMENT AMERICAS INC | 349.4K +8.0K (+2.4%) | 27.83M +11.9M (+74.6%) | 0.18% +0.003 pp | 0.01% +0.002 pp | USD36.54 +118.0% | 22 qtrs — |
| 77 | BOOTHBAY FUND MANAGEMENT, LLC | 327.2K +62.1K (+23.4%) | 26.06M +13.7M (+110.6%) | 0.17% +0.032 pp | 0.39% +0.209 pp | USD46.56 +71.1% | 4 qtrs — |
| 78 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 322.3K +173.1K (+116.1%) | 25.67M +18.7M (+268.6%) | 0.17% +0.091 pp | 0.09% +0.067 pp | USD63.35 +25.7% | 8 qtrs — |
| 79 | NICHOLAS INVESTMENT PARTNERS, LP | 317.7K +49.8K (+18.6%) | 25.31M +12.8M (+102.3%) | 0.17% +0.026 pp | 1.84% +0.887 pp | USD48.98 +62.6% | 7 qtrs — |
| 80 | JENNISON ASSOCIATES LLC | 305.3K +305.3K (+100.0%) | 24.31M +24.3M (+100.0%) | 0.16% +0.161 pp | 0.01% +0.015 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 81 | VESTAL POINT CAPITAL, LP | 295.0K -335.0K (-53.2%) | 23.50M -5.9M (-20.1%) | 0.16% -0.179 pp | 0.80% -0.530 pp | USD36.79 +116.5% | 3 qtrs — |
| 82 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 291.0K +60.0K (+26.0%) | 23.18M +12.4M (+114.9%) | 0.15% +0.031 pp | 0.01% +0.007 pp | USD52.28 +52.4% | 6 qtrs — |
| 83 | TWO SIGMA ADVISERS, LP | 287.6K +248.7K (+637.7%) | 22.91M +21.1M (+1,158.2%) | 0.15% +0.131 pp | 0.04% +0.041 pp | USD75.18 +5.9% | 2 qtrs — |
| 84 | SWISS NATIONAL BANK | 276.3K +5.5K (+2.0%) | 22.01M +9.4M (+74.0%) | 0.15% +0.002 pp | 0.01% +0.006 pp | USD31.73 +151.0% | 23 qtrs — |
| 85 | RAYMOND JAMES FINANCIAL INC | 244.2K -34.0K (-12.2%) | 19.45M +6.5M (+49.7%) | 0.13% -0.019 pp | 0.01% +0.002 pp | USD43.74 +82.1% | 5 qtrs — |
| 86 | FISHER ASSET MANAGEMENT, LLC | 241.1K +233.8K (+3,199.9%) | 19.20M +18.9M (+5,528.2%) | 0.13% +0.124 pp | 0.01% +0.006 pp | USD78.65 +1.3% | 2 qtrs — |
| 87 | ALYESKA INVESTMENT GROUP, L.P. | 239.1K +239.1K (+100.0%) | 19.04M +19.0M (+100.0%) | 0.13% +0.126 pp | 0.05% +0.054 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 88 | ENSIGN PEAK ADVISORS, INC | 235.8K -12.7K (-5.1%) | 18.78M +7.2M (+61.9%) | 0.12% -0.008 pp | 0.03% +0.014 pp | USD40.68 +95.8% | 17 qtrs — |
| 89 | CATALYST FUNDS MANAGEMENT PTY LTD | 223.6K +13.4K (+6.4%) | 17.81M +8.0M (+81.4%) | 0.12% +0.006 pp | 4.13% +2.649 pp | USD46.65 +70.7% | 3 qtrs — |
| 90 | MARSICO CAPITAL MANAGEMENT LLC | 219.5K +219.5K (+100.0%) | 17.48M +17.5M (+100.0%) | 0.12% +0.116 pp | 0.49% +0.487 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 91 | BALYASNY ASSET MANAGEMENT L.P. | 215.0K +215.0K (+100.0%) | 17.12M +17.1M (+100.0%) | 0.11% +0.114 pp | 0.02% +0.022 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 92 | DECHENG CAPITAL LLC | 200.0K -10.0K (-4.8%) | 15.93M +6.1M (+62.4%) | 0.11% -0.006 pp | 2.14% +0.432 pp | USD43.75 +82.1% | 6 qtrs — |
| 93 | BAILLIE GIFFORD & CO | 195.0K +195.0K (+100.0%) | 15.53M +15.5M (+100.0%) | 0.10% +0.103 pp | 0.01% +0.013 pp | USD79.65 +0.0% | 1 qtrs NEW |
| 94 | VERITION FUND MANAGEMENT LLC | 189.3K +53.9K (+39.8%) | 15.08M +8.8M (+138.4%) | 0.10% +0.028 pp | 0.06% +0.033 pp | USD48.89 +62.9% | 6 qtrs — |
| 95 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 183.2K +65.0K (+55.0%) | 14.59M +9.1M (+164.4%) | 0.10% +0.034 pp | 0.00% +0.001 pp | USD52.32 +52.2% | 24 qtrs — |
| 96 | A16Z PERENNIAL MANAGEMENT, L.P. | 182.9K +182.9K (+100.0%) | 14.57M +14.6M (+100.0%) | 0.10% +0.097 pp | 1.09% +1.095 pp | USD79.65 +0.0% | 3 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.43
Bearish
Ratio by volume
0.50
Neutral
Buys
3
Sells
7
Shares acquired
123.1K
Shares disposed
246.2K
Cash buys
—
Cash sales
4.00
Net activity
-123,120
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Mancini Anthony | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,120 | 33.62 | 104.9K | 109,230 | D | ↗ |
| 2026-04-15 | GOLDSMITH MARK A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 96,756 | 4.73 | 457.7K | 424,085 | D | ↗ |
| 2026-03-25 | Mancini Anthony | Officer | S-Sale | D | Common Stock | 3,128 | 94.16 | 294.5K | 86,922 | D | ↗ |
| 2026-03-20 | Sandler Alan B. | Officer | — | — | Common Stock | 0 | 0.00 | — | 53,000 | D | ↗ |
| 2026-03-20 | Mancini Anthony | Officer | — | — | Common Stock | 0 | 0.00 | — | 54,400 | D | ↗ |
| 2026-03-19 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,163 | 97.44 | 113.3K | 58,518 | D | ↗ |
| 2026-03-17 | Wei Lin | Officer | S-Sale | D | Common Stock | 2,073 | 99.48 | 206.2K | 101,366 | D | ↗ |
| 2026-03-17 | Wang Xiaolin | Officer | S-Sale | D | Common Stock | 2,010 | 99.48 | 200.0K | 116,063 | D | ↗ |
| 2026-03-17 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 4,302 | 99.48 | 428.0K | 295,398 | D | ↗ |
| 2026-03-17 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 4,583 | 99.48 | 455.9K | 157,570 | D | ↗ |
| 2026-03-17 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 12,871 | 99.48 | 1.28M | 276,698 | D | ↗ |
| 2026-03-17 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,795 | 99.48 | 178.6K | 59,681 | D | ↗ |
| 2026-03-17 | Anders Jack | Officer | S-Sale | D | Common Stock | 2,753 | 99.48 | 273.9K | 125,512 | D | ↗ |
| 2026-03-04 | ANDERSON ELIZABETH M | Director | G-Gift | A | Common Stock | 15,000 | 0.00 | — | 15,000 | I | ↗ |
| 2026-03-02 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 3,620 | 100.73 | 364.7K | 311,749 | D | ↗ |
| 2026-03-01 | Wei Lin | Officer | A-Award | A | Stock Option (Right to Buy) | 34,000 | 102.02 | 3.47M | 34,000 | D | ↗ |
| 2026-03-01 | Wang Xiaolin | Officer | A-Award | A | Stock Option (Right to Buy) | 34,000 | 102.02 | 3.47M | 34,000 | D | ↗ |
| 2026-03-01 | Kelsey Stephen Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 47,600 | 102.02 | 4.86M | 47,600 | D | ↗ |
| 2026-03-01 | Horn Margaret A | Officer | A-Award | A | Stock Option (Right to Buy) | 47,600 | 102.02 | 4.86M | 47,600 | D | ↗ |
| 2026-03-01 | GOLDSMITH MARK A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 128,600 | 102.02 | 13.12M | 128,600 | D | ↗ |
| 2026-03-01 | Cislini Jeff | Officer | A-Award | A | Common Stock | 14,500 | 0.00 | — | 61,476 | D | ↗ |
| 2026-03-01 | Anders Jack | Officer | A-Award | A | Common Stock | 20,200 | 0.00 | — | 128,265 | D | ↗ |
| 2026-02-06 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 24,010 | 0.54 | 13.0K | 256,479 | D | ↗ |
| 2026-01-21 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 908 | 115.60 | 105.0K | 46,976 | D | ↗ |
| 2026-01-07 | Horn Margaret A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 23,594 | 29.80 | 703.1K | 119,906 | D | ↗ |
| 2026-01-07 | Anders Jack | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 42.45 | 424.5K | 15,900 | D | ↗ |
| 2025-12-16 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 5,447 | 76.82 | 418.4K | 278,600 | D | ↗ |
| 2025-12-16 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 4,847 | 76.82 | 372.3K | 141,053 | D | ↗ |
| 2025-12-16 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 15,394 | 76.82 | 1.18M | 232,469 | D | ↗ |
| 2025-12-16 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 2,688 | 76.82 | 206.5K | 47,884 | D | ↗ |
| 2025-12-16 | Anders Jack | Officer | S-Sale | D | Common Stock | 3,104 | 77.09 | 239.3K | 108,065 | D | ↗ |
| 2025-11-25 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 3,000 | 75.00 | 225.0K | 67,424 | I | ↗ |
| 2025-11-25 | Anders Jack | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,418 | 17.00 | 92.1K | 0 | D | ↗ |
| 2025-11-18 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 20,000 | 4.09 | 81.8K | 267,863 | D | ↗ |
| 2025-11-18 | Cislini Jeff | Officer | M-Exempt | A | Common Stock | 13,388 | 42.45 | 568.3K | 63,813 | D | ↗ |
| 2025-11-12 | GOLDSMITH MARK A | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 297,863 | D | ↗ |
| 2025-11-11 | Anders Jack | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 17.00 | 170.0K | 5,418 | D | ↗ |
| 2025-11-07 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 26,479 | 1.12 | 29.7K | 374,342 | D | ↗ |
| 2025-10-13 | Kelsey Stephen Michael | Officer | M-Exempt | A | Common Stock | 25,000 | 4.73 | 118.3K | 309,047 | D | ↗ |
| 2025-09-24 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,799 | 44.26 | 79.6K | 50,425 | D | ↗ |
| 2025-09-16 | Wei Lin | Officer | S-Sale | D | Common Stock | 2,160 | 45.82 | 99.0K | 88,339 | D | ↗ |
| 2025-09-16 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 5,367 | 45.82 | 245.9K | 284,047 | D | ↗ |
| 2025-09-16 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 4,775 | 45.82 | 218.8K | 145,900 | D | ↗ |
| 2025-09-16 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 13,411 | 45.82 | 614.6K | 452,309 | D | ↗ |
| 2025-09-16 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,869 | 45.82 | 85.6K | 52,224 | D | ↗ |
| 2025-09-16 | Anders Jack | Officer | S-Sale | D | Common Stock | 2,320 | 45.82 | 106.3K | 110,994 | D | ↗ |
| 2025-09-15 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 1,318 | 46.93 | 61.9K | 289,414 | D | ↗ |
| 2025-09-11 | Kelsey Stephen Michael | Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 4.73 | 473.0K | 55,055 | D | ↗ |
| 2025-09-03 | Anders Jack | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,049 | 17.00 | 34.8K | 15,418 | D | ↗ |
| 2025-09-02 | Anders Jack | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,814 | 2.68 | 7.5K | 0 | D | ↗ |
| 2025-06-30 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 37,000 | 0.54 | 20.0K | 465,720 | D | ↗ |
| 2025-06-26 | Patel Sushil | Director | A-Award | A | Stock Option (Right to Buy) | 11,574 | 37.48 | 433.8K | 11,574 | D | ↗ |
| 2025-06-26 | Kim Lorence H. | Director | A-Award | A | Stock Option (Right to Buy) | 11,574 | 37.48 | 433.8K | 11,574 | D | ↗ |
| 2025-06-26 | Horning Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 11,574 | 37.48 | 433.8K | 11,574 | D | ↗ |
| 2025-06-26 | Clyburn Frank | Director | A-Award | A | Common Stock | 2,806 | 0.00 | — | 9,738 | D | ↗ |
| 2025-06-26 | Borisy Alexis | Director | A-Award | A | Stock Option (Right to Buy) | 11,574 | 37.48 | 433.8K | 11,574 | D | ↗ |
| 2025-06-26 | Borellini Flavia | Director | A-Award | A | Stock Option (Right to Buy) | 11,574 | 37.48 | 433.8K | 11,574 | D | ↗ |
| 2025-06-26 | ANDERSON ELIZABETH M | Director | A-Award | A | Stock Option (Right to Buy) | 11,574 | 37.48 | 433.8K | 11,574 | D | ↗ |
| 2025-06-20 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,912 | 39.61 | 75.7K | 54,093 | D | ↗ |
| 2025-06-16 | Wei Lin | Officer | S-Sale | D | Common Stock | 2,173 | 39.83 | 86.6K | 90,499 | D | ↗ |
| 2025-06-16 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 4,289 | 39.83 | 170.8K | 289,414 | D | ↗ |
| 2025-06-16 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 3,510 | 39.83 | 139.8K | 150,675 | D | ↗ |
| 2025-06-16 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 13,496 | 39.83 | 537.5K | 428,720 | D | ↗ |
| 2025-06-16 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,878 | 39.83 | 74.8K | 56,005 | D | ↗ |
| 2025-06-16 | Anders Jack | Officer | S-Sale | D | Common Stock | 2,170 | 39.83 | 86.4K | 113,314 | D | ↗ |
| 2025-03-20 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 2,041 | 38.71 | 79.0K | 57,723 | D | ↗ |
| 2025-03-17 | Wang Xiaolin | Officer | G-Gift | D | Common Stock | 2,718 | 0.00 | — | 102,321 | D | ↗ |
| 2025-03-17 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 3,294 | 39.04 | 128.6K | 293,051 | D | ↗ |
| 2025-03-17 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 3,058 | 39.04 | 119.4K | 153,533 | D | ↗ |
| 2025-03-17 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 11,738 | 39.04 | 458.3K | 441,564 | D | ↗ |
| 2025-03-17 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,458 | 39.04 | 56.9K | 59,764 | D | ↗ |
| 2025-03-17 | Anders Jack | Officer | S-Sale | D | Common Stock | 1,864 | 39.04 | 72.8K | 115,006 | D | ↗ |
| 2025-03-01 | Wei Lin | Officer | A-Award | D | Common Stock | 20,800 | 0.00 | — | 91,651 | D | ↗ |
| 2025-03-01 | Wang Xiaolin | Officer | A-Award | A | Common Stock | 19,000 | 0.00 | — | 105,039 | D | ↗ |
| 2025-03-01 | Kelsey Stephen Michael | Officer | A-Award | A | Common Stock | 36,600 | 0.00 | — | 296,345 | D | ↗ |
| 2025-03-01 | Horn Margaret A | Officer | A-Award | A | Common Stock | 28,600 | 0.00 | — | 156,591 | D | ↗ |
| 2025-03-01 | GOLDSMITH MARK A | Director / Officer | A-Award | A | Common Stock | 97,400 | 0.00 | — | 453,302 | D | ↗ |
| 2025-03-01 | Cislini Jeff | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 61,222 | D | ↗ |
| 2025-03-01 | Anders Jack | Officer | A-Award | A | Stock Option (Right to Buy) | 71,400 | 40.74 | 2.91M | 71,400 | D | ↗ |
| 2025-01-21 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 2,406 | 40.50 | 97.4K | 39,222 | D | ↗ |
| 2024-12-18 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 30,846 | 0.49 | 15.1K | 355,902 | D | ↗ |
| 2024-12-16 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 4,663 | 45.40 | 211.7K | 259,745 | D | ↗ |
| 2024-12-16 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 4,329 | 45.40 | 196.6K | 127,991 | D | ↗ |
| 2024-12-16 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 11,714 | 45.40 | 531.9K | 325,056 | D | ↗ |
| 2024-12-16 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,599 | 45.40 | 72.6K | 41,628 | D | ↗ |
| 2024-12-16 | Anders Jack | Officer | S-Sale | D | Common Stock | 2,635 | 45.40 | 119.6K | 96,470 | D | ↗ |
| 2024-12-05 | Schroeder Thilo | Director | P-Purchase | A | Common Stock | 760,869 | 46.00 | 35.00M | 760,869 | I | ↗ |
| 2024-11-15 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 2,554 | 55.13 | 140.8K | 43,080 | D | ↗ |
| 2024-11-13 | Kelsey Stephen Michael | Officer | M-Exempt | A | Common Stock | 16,666 | 4.09 | 68.2K | 281,074 | D | ↗ |
| 2024-11-06 | Cislini Jeff | Officer | M-Exempt | A | Common Stock | 6,000 | 36.57 | 219.4K | 51,634 | D | ↗ |
| 2024-11-04 | GOLDSMITH MARK A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 50,900 | 4.09 | 208.2K | 181,229 | D | ↗ |
| 2024-11-01 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 5,000 | 55.03 | 275.1K | 20,424 | I | ↗ |
| 2024-10-31 | Patel Sushil | Director | M-Exempt | A | Common Stock | 5,000 | 24.84 | 124.2K | 24,948 | D | ↗ |
| 2024-10-14 | Kelsey Stephen Michael | Officer | M-Exempt | A | Common Stock | 16,666 | 4.09 | 68.2K | 281,074 | D | ↗ |
| 2024-10-11 | Horn Margaret A | Officer | M-Exempt | A | Common Stock | 5,369 | 4.09 | 22.0K | 182,320 | D | ↗ |
| 2024-10-11 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 4.09 | 122.7K | 330,170 | D | ↗ |
| 2024-10-11 | Cislini Jeff | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,000 | 36.57 | 219.4K | 36,000 | D | ↗ |
| 2024-10-11 | Anders Jack | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 2.68 | 26.8K | 2,814 | D | ↗ |
| 2024-10-08 | Weber Barbara | Director | S-Sale | D | Common Stock | 5,200 | 48.02 | 249.7K | 13,065 | D | ↗ |
| 2024-10-01 | GOLDSMITH MARK A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 4.09 | 40.9K | 271,229 | D | ↗ |
| 2024-09-16 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 4,665 | 44.19 | 206.1K | 264,408 | — | ↗ |
| 2024-09-16 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 4,331 | 44.19 | 191.4K | 132,320 | — | ↗ |
| 2024-09-16 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 11,715 | 44.19 | 517.6K | 300,170 | — | ↗ |
| 2024-09-16 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,454 | 44.19 | 64.2K | 45,634 | — | ↗ |
| 2024-09-16 | Anders Jack | Officer | S-Sale | D | Common Stock | 2,244 | 44.19 | 99.2K | 98,932 | — | ↗ |
| 2024-09-13 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 5,966 | 42.75 | 255.0K | 279,774 | — | ↗ |
| 2024-08-21 | Weber Barbara | Director | D-Return | D | Common Stock | 1,808 | 44.83 | 81.1K | 18,265 | — | ↗ |
| 2024-08-13 | Kelsey Stephen Michael | Officer | M-Exempt | A | Common Stock | 16,667 | 4.09 | 68.2K | 285,740 | — | ↗ |
| 2024-08-05 | Clyburn Frank | Director | A-Award | A | Stock Option (Right to Buy) | 26,540 | 42.48 | 1.13M | 26,540 | D | ↗ |
| 2024-08-01 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 3,217 | 46.48 | 149.5K | 311,885 | — | ↗ |
| 2024-07-15 | Kelsey Stephen Michael | Officer | M-Exempt | D | Stock Option (Right to Buy) | 16,667 | 4.09 | 68.2K | 73,332 | — | ↗ |
| 2024-07-12 | GOLDSMITH MARK A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 4.09 | 102.3K | 291,229 | — | ↗ |
| 2024-07-09 | Patel Sushil | Director | S-Sale | D | Common Stock | 2,155 | 44.00 | 94.8K | 19,948 | — | ↗ |
| 2024-07-09 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 2,399 | 40.83 | 98.0K | 47,088 | — | ↗ |
| 2024-06-26 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 2,000 | 38.47 | 76.9K | 49,487 | — | ↗ |
| 2024-06-25 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 16,467 | 39.06 | 643.2K | 269,073 | — | ↗ |
| 2024-06-24 | Kelsey Stephen Michael | Officer | M-Exempt | D | Stock Option (Right to Buy) | 200 | 4.09 | 818.00 | 106,466 | — | ↗ |
| 2024-06-20 | Weber Barbara | Director | A-Award | A | Common Stock | 4,800 | 0.00 | — | 20,625 | — | ↗ |
| 2024-06-20 | Patel Sushil | Director | A-Award | A | Stock Option (Right to Buy) | 16,700 | 37.54 | 626.9K | 16,700 | — | ↗ |
| 2024-06-20 | Kim Lorence H. | Director | A-Award | A | Common Stock | 4,800 | 0.00 | — | 70,500 | — | ↗ |
| 2024-06-20 | Horning Sandra | Director | A-Award | A | Common Stock | 4,800 | 0.00 | — | 95,287 | — | ↗ |
| 2024-06-20 | Borisy Alexis | Director | A-Award | A | Common Stock | 4,800 | 0.00 | — | 2,336,294 | — | ↗ |
| 2024-06-20 | Borellini Flavia | Director | A-Award | A | Stock Option (Right to Buy) | 15,955 | 37.54 | 599.0K | 15,955 | — | ↗ |
| 2024-06-20 | ANDERSON ELIZABETH M | Director | A-Award | A | Common Stock | 4,800 | 0.00 | — | 20,625 | — | ↗ |
| 2024-06-17 | Wei Lin | Officer | S-Sale | D | Common Stock | 5,589 | 37.39 | 209.0K | 70,851 | — | ↗ |
| 2024-06-17 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 3,349 | 37.39 | 125.2K | 269,073 | — | ↗ |
| 2024-06-17 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 4,415 | 37.39 | 165.1K | 136,651 | — | ↗ |
| 2024-06-17 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 11,950 | 37.39 | 446.8K | 311,885 | — | ↗ |
| 2024-06-17 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,757 | 37.39 | 65.7K | 51,487 | — | ↗ |
| 2024-06-17 | Anders Jack | Officer | S-Sale | D | Common Stock | 1,893 | 37.39 | 70.8K | 101,176 | — | ↗ |
| 2024-06-03 | GOLDSMITH MARK A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 4.09 | 30.7K | 316,229 | — | ↗ |
| 2024-05-21 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 700 | 38.67 | 27.1K | 53,674 | — | ↗ |
| 2024-05-03 | Anders Jack | Officer | M-Exempt | A | Common Stock | 10,000 | 2.68 | 26.8K | 111,959 | — | ↗ |
| 2024-04-10 | Patel Sushil | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,155 | 16.80 | 36.2K | 34,645 | — | ↗ |
| 2024-04-10 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 7,500 | 35.48 | 266.1K | 452,879 | — | ↗ |
| 2024-03-27 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 700 | 30.38 | 21.3K | 55,174 | — | ↗ |
| 2024-03-21 | Wei Lin | Officer | — | D | Stock Option (Right to Buy) | 200,000 | 23.85 | 4.77M | 0 | — | ↗ |
| 2024-03-18 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 2,123 | 31.58 | 67.1K | 270,909 | — | ↗ |
| 2024-03-18 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 2,914 | 31.58 | 92.0K | 139,553 | — | ↗ |
| 2024-03-18 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 5,788 | 31.58 | 182.8K | 460,379 | — | ↗ |
| 2024-03-18 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,252 | 31.58 | 39.5K | 55,874 | — | ↗ |
| 2024-03-18 | Anders Jack | Officer | S-Sale | D | Common Stock | 1,261 | 31.58 | 39.8K | 101,959 | — | ↗ |
| 2024-03-12 | Horn Margaret A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,936 | 4.09 | 32.5K | 44,631 | — | ↗ |
| 2024-03-11 | Horn Margaret A | Officer | M-Exempt | A | Common Stock | 15,735 | 4.09 | 64.4K | 158,202 | — | ↗ |
| 2024-03-01 | Wang Xiaolin | Officer | A-Award | A | Common Stock | 24,200 | 0.00 | — | 84,526 | — | ↗ |
| 2024-03-01 | Kelsey Stephen Michael | Officer | A-Award | A | Common Stock | 51,400 | 0.00 | — | 273,032 | — | ↗ |
| 2024-03-01 | Horn Margaret A | Officer | A-Award | A | Common Stock | 41,000 | 0.00 | — | 142,467 | — | ↗ |
| 2024-03-01 | GOLDSMITH MARK A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 314,000 | 29.80 | 9.36M | 314,000 | — | ↗ |
| 2024-03-01 | Cislini Jeff | Officer | A-Award | A | Common Stock | 21,000 | 0.00 | — | 57,126 | — | ↗ |
| 2024-03-01 | Anders Jack | Officer | A-Award | A | Stock Option (Right to Buy) | 92,400 | 29.80 | 2.75M | 92,400 | — | ↗ |
| 2024-01-22 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,500 | 27.00 | 40.5K | 36,126 | — | ↗ |
| 2024-01-08 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 3,337 | 29.01 | 96.8K | 221,632 | — | ↗ |
| 2024-01-02 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 13,330 | 29.10 | 387.9K | 224,969 | — | ↗ |
| 2023-12-27 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 33,334 | 29.01 | 967.0K | 238,299 | — | ↗ |
| 2023-12-18 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 2,088 | 25.90 | 54.1K | 271,633 | — | ↗ |
| 2023-12-18 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 2,993 | 25.90 | 77.5K | 101,467 | — | ↗ |
| 2023-12-18 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 8,165 | 25.90 | 211.5K | 376,167 | — | ↗ |
| 2023-12-18 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,229 | 25.90 | 31.8K | 37,284 | — | ↗ |
| 2023-12-18 | Anders Jack | Officer | S-Sale | D | Common Stock | 1,775 | 25.90 | 46.0K | 76,416 | — | ↗ |
| 2023-12-15 | Horn Margaret A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 4.09 | 20.5K | 68,302 | — | ↗ |
| 2023-12-06 | Horn Margaret A | Officer | M-Exempt | A | Common Stock | 5,000 | 4.09 | 20.5K | 109,460 | — | ↗ |
| 2023-11-20 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,500 | 21.70 | 32.5K | 38,513 | — | ↗ |
| 2023-11-09 | Schroeder Thilo | Director | A-Award | A | Earn-out Shares | 70,035 | 0.00 | — | 70,035 | — | ↗ |
| 2023-11-09 | Horning Sandra | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-09 | Borisy Alexis | Director | A-Award | A | Common Stock | 2,091,672 | 0.00 | — | 2,331,494 | — | ↗ |
| 2023-10-25 | Horn Margaret A | Officer | M-Exempt | A | Common Stock | 7,500 | 0.54 | 4.1K | 104,460 | — | ↗ |
| 2023-10-24 | GOLDSMITH MARK A | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 35,000 | 0.49 | 17.2K | 67,446 | — | ↗ |
| 2023-10-23 | Anders Jack | Officer | M-Exempt | A | Common Stock | 5,137 | 4.09 | 21.0K | 78,191 | — | ↗ |
| 2023-10-16 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 800 | 33.23 | 26.6K | 120,560 | — | ↗ |
| 2023-10-11 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 16,667 | 29.05 | 484.1K | 273,721 | — | ↗ |
| 2023-09-28 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,798 | 28.10 | 50.5K | 40,215 | — | ↗ |
| 2023-09-18 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 2,060 | 31.31 | 64.5K | 290,388 | — | ↗ |
| 2023-09-18 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 2,514 | 31.31 | 78.7K | 96,960 | — | ↗ |
| 2023-09-18 | GOLDSMITH MARK A | Director / Officer | S-Sale | D | Common Stock | 8,054 | 31.31 | 252.2K | 349,332 | — | ↗ |
| 2023-09-18 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,214 | 31.31 | 38.0K | 42,013 | — | ↗ |
| 2023-09-18 | Anders Jack | Officer | S-Sale | D | Common Stock | 1,427 | 31.31 | 44.7K | 53,667 | — | ↗ |
| 2023-09-15 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 5,000 | 32.08 | 160.4K | 99,474 | — | ↗ |
| 2023-09-01 | Weber Barbara | Director | M-Exempt | A | Common Stock | 11,146 | 4.73 | 52.7K | 30,825 | — | ↗ |
| 2023-09-01 | GOLDSMITH MARK A | Director / Officer | M-Exempt | A | Common Stock | 12,007 | 1.12 | 13.4K | 387,386 | — | ↗ |
| 2023-09-01 | Anders Jack | Officer | M-Exempt | A | Common Stock | 20,000 | 2.68 | 53.6K | 75,094 | — | ↗ |
| 2023-08-31 | Horn Margaret A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 4.09 | 40.9K | 108,302 | — | ↗ |
| 2023-08-15 | Horn Margaret A | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 4.09 | 20.5K | 118,302 | — | ↗ |
| 2023-08-02 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 16,666 | 32.40 | 540.0K | 292,448 | — | ↗ |
| 2023-08-01 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 16,666 | 29.19 | 486.5K | 309,114 | — | ↗ |
| 2023-07-31 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,500 | 26.02 | 39.0K | 43,227 | — | ↗ |
| 2023-06-20 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 2,102 | 24.89 | 52.3K | 325,780 | — | ↗ |
| 2023-06-20 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 2,102 | 24.89 | 52.3K | 99,474 | — | ↗ |
| 2023-06-20 | Cislini Jeff | Officer | S-Sale | D | Common Stock | 1,239 | 25.14 | 31.1K | 44,727 | — | ↗ |
| 2023-06-20 | Anders Jack | Officer | S-Sale | D | Common Stock | 1,249 | 24.89 | 31.1K | 55,094 | — | ↗ |
| 2023-06-08 | Weber Barbara | Director | A-Award | A | Common Stock | 5,200 | 0.00 | — | 15,825 | — | ↗ |
| 2023-06-08 | SCHMIDT ERIC THOMAS | Director | A-Award | A | Common Stock | 5,200 | 0.00 | — | 21,251 | — | ↗ |
| 2023-06-08 | Patel Sushil | Director | A-Award | A | Common Stock | 5,200 | 0.00 | — | 15,700 | — | ↗ |
| 2023-06-08 | Kim Lorence H. | Director | A-Award | A | Stock Option (Right to Buy) | 18,400 | 24.84 | 457.1K | 18,400 | — | ↗ |
| 2023-06-08 | Borisy Alexis | Director | A-Award | A | Stock Option (Right to Buy) | 18,400 | 24.84 | 457.1K | 18,400 | — | ↗ |
| 2023-06-08 | Borellini Flavia | Director | A-Award | A | Common Stock | 5,200 | 0.00 | — | 17,634 | — | ↗ |
| 2023-06-08 | ANDERSON ELIZABETH M | Director | A-Award | A | Stock Option (Right to Buy) | 18,400 | 24.84 | 457.1K | 18,400 | — | ↗ |
| 2023-03-23 | Cislini Jeff | Officer | — | D | Common Stock | 0 | 0.00 | — | 45,596 | — | ↗ |
| 2023-03-17 | Wang Xiaolin | Officer | S-Sale | D | Common Stock | 714 | 21.78 | 15.6K | 58,813 | — | ↗ |
| 2023-03-17 | Kelsey Stephen Michael | Officer | S-Sale | D | Common Stock | 1,230 | 21.78 | 26.8K | 326,369 | — | ↗ |
| 2023-03-17 | Horn Margaret A | Officer | S-Sale | D | Common Stock | 1,230 | 21.78 | 26.8K | 100,062 | — | ↗ |
Executive team
Top executives
Shares Outstanding
212.59M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | 689.2K | — | 2.68M | 6.05M | 651.8K | 7.0K | 10.08M | 86.63% | ↗ |
| 2 | 2024 | Steve Kelsey, M.D., FRCP, FRCPath President, Research and Development | 573.3K | — | 1.53M | 3.47M | 371.6K | 7.0K | 5.95M | 84.00% | ↗ |
| 3 | 2024 | Margaret Horn, J.D. Chief Operating Officer | 540.8K | — | 1.22M | 2.76M | 350.1K | 7.0K | 4.88M | 81.62% | ↗ |
| 4 | 2024 | Jack Anders Chief Financial Officer | 473.3K | — | 786.7K | 1.78M | 245.3K | 7.0K | 3.29M | 77.96% | ↗ |
| 5 | 2024 | Xiaolin Wang, Sc.D. Executive Vice President, Development | 455.5K | — | 721.2K | 1.63M | 238.7K | 7.0K | 3.05M | 77.04% | ↗ |
| 6 | 2023 | Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | 631.1K | — | 2.76M | 6.54M | 477.1K | 7.0K | 10.41M | 89.29% | ↗ |
| 7 | 2023 | Steve Kelsey, M.D., FRCP, FRCPath President, Research and Development | 512.6K | — | 1.06M | 2.52M | 292.6K | 7.0K | 4.39M | 81.52% | ↗ |
| 8 | 2023 | Margaret Horn, J.D. Chief Operating Officer | 512.6K | — | 1.06M | 2.52M | 291.5K | 7.0K | 4.39M | 81.54% | ↗ |
| 9 | 2023 | Xiaolin Wang, Sc.D. Executive Vice President, Development | 415.7K | — | 768.5K | 1.83M | 211.0K | 7.0K | 3.23M | 80.39% | ↗ |
| 10 | 2023 | Jack Anders Chief Financial Officer | 438.4K | — | 704.9K | 1.68M | 219.9K | 7.0K | 3.05M | 78.17% | ↗ |
| 11 | 2022 | Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | 606.7K | — | 1.93M | 4.23M | 439.9K | 7.0K | 7.22M | 85.40% | ↗ |
| 12 | 2022 | Steve Kelsey, M.D. President, Research and Development | 497.5K | — | 720.1K | 1.58M | 274.5K | 7.0K | 3.08M | 74.73% | ↗ |
| 13 | 2022 | Steve Kelsey, M.D., FRCP, FRCPath President, Research and Development | 497.5K | — | 720.1K | 1.58M | 274.5K | 7.0K | 3.08M | 74.73% | ↗ |
| 14 | 2022 | Margaret Horn, J.D. Chief Operating Officer | 497.5K | — | 720.1K | 1.58M | 271.1K | 7.0K | 3.08M | 74.82% | ↗ |
| 15 | 2022 | Jack Anders Chief Financial Officer | 371.0K | — | 431.4K | 971.3K | 166.8K | 7.0K | 1.95M | 72.03% | ↗ |
| 16 | 2022 | Xiaolin Wang Sc.D. Executive Vice President and Clinical Development | 400.0K | — | 371.2K | 816.5K | 197.1K | 7.0K | 1.79M | 66.28% | ↗ |
| 17 | 2022 | Xiaolin Wang, Sc.D. Executive Vice President, Development | 400.0K | — | 371.2K | 816.5K | 197.1K | 7.0K | 1.79M | 66.28% | ↗ |
| 18 | 2021 | Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | 580.8K | — | 2.04M | 4.79M | 418.3K | 7.0K | 7.83M | 87.15% | ↗ |
| 19 | 2021 | Margaret Horn, J.D. Chief Operating Officer and General Counsel | 482.3K | — | 636.8K | 1.49M | 283.7K | 7.0K | 2.90M | 73.31% | ↗ |
| 20 | 2021 | Steve Kelsey, M.D. President, Research and Development | 482.3K | — | 636.8K | 1.49M | 283.7K | 7.0K | 2.90M | 73.31% | ↗ |
| 21 | 2021 | Margaret Horn, J.D. Chief Operating Officer | 482.3K | — | 636.8K | 1.49M | 283.7K | 7.0K | 2.90M | 73.31% | ↗ |
| 22 | 2021 | Xiaolin Wang Sc.D. Executive Vice President and Clinical Development | 377.8K | — | 475.4K | 1.11M | 197.6K | 7.0K | 2.17M | 73.13% | ↗ |
| 23 | 2021 | Xiaolin Wang Sc.D. Executive Vice President and Clinical Development | 377.8K | — | 475.4K | 1.11M | 197.6K | 7.0K | 2.17M | 73.13% | ↗ |
| 24 | 2021 | Jack Anders Chief Financial Officer | 311.3K | — | 314.1K | 733.4K | 143.8K | 7.0K | 1.51M | 69.39% | ↗ |
| 25 | 2021 | Jack Anders Chief Financial Officer | 311.3K | — | 314.1K | 733.4K | 143.8K | 7.0K | 1.51M | 69.39% | ↗ |
| 26 | 2020 | Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | 554.0K | — | — | 1.43M | 406.0K | 2.0K | 2.39M | 59.72% | ↗ |
| 27 | 2020 | Steve Kelsey, M.D. President, Research and Development | 464.2K | — | — | 522.6K | 273.7K | 2.0K | 1.26M | 41.39% | ↗ |
| 28 | 2020 | Margaret Horn, J.D. Chief Operating Officer and General Counsel | 459.7K | — | — | 522.6K | 273.7K | 2.0K | 1.26M | 41.54% | ↗ |
| 29 | 2019 | Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | 504.3K | — | — | 3.81M | 261.0K | 2.0K | 4.58M | 83.23% | ↗ |
| 30 | 2019 | Margaret Horn, J.D. Chief Operating Officer and General Counsel | 384.4K | — | — | 1.66M | 166.2K | 2.0K | 2.22M | 75.06% | ↗ |
| 31 | 2019 | Steve Kelsey, M.D. President, Research and Development | 424.4K | — | — | 1.30M | 170.8K | 2.0K | 1.90M | 68.49% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark A. Goldsmith | Chief Executive Officer, President & Chairman | 2M | — |
| Stephen Kelsey Path. FRCP | President of Research & Development | 1M | — |
| Margaret A. Horn | Chief Operating Officer | 1M | female |
| Jack Anders | Chief Financial Officer | 874.1K | male |
| Jeff Cislini | Senior Vice President, General Counsel & Corporate Secretary | 791.8K | male |
| Xiaolin Wang | Executive Vice President of Development | 701.2K | female |
| Kevan Shokat | Academic Co-Founder & Member of Scientific Advisory Board | — | — |
| Jan Smith | Chief Scientific Officer | — | female |
| Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board | — | — |
| Michael A. Fischbach | Academic Co-Founder & Member of Scientific Advisory Board | — | — |
| Erin Graves | Senior Director of Corporate Communications & Investor Relations | — | female |
| Walter Reiher | Chief Information Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RVMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
